Sun, Dec 28, 2014, 7:49 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • mbr041076 mbr041076 Dec 6, 2011 2:30 PM Flag

    If you are right

    still dont trust FDA/politicans meaning your very own congress,senators who have privy to what will pass and what wont.These people are in contact with FDA.Get it FEDERAL,this is how they make their millions and its not against the law! for us like Martha Stewart we go to prison.Do you think for one moment this part of the Goverment is honest?I dont think so,sorry but its as crooked as my dogs back leg!!!! Too much money involved it will pass regardless of soc or anything else that why wall street has made VRUS its golden boy.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I agree the FDA may approve Pharmasset's oral regimen for patients intolerant of interferon, regarless of genotype. The problem will be getting the docs who prescribe these meds to favor an expensive oral regimen with a lower cure rate over Incivek/interferon/RBV. There is a lot of talk about an oral HCV regimen being the "Holy Grail" of HCV treatment but what really matters is if you can cure the patient.

      • 2 Replies to swhitemd50
      • you are right about the doctors,but if it will cure the 2&3s they will get the oral.Its a big market I just wish Vertex would let us know how are oral combo is comming along.As far as the FDA I dont have anything good to say about them.To let a company NOT be compared to the SOC or better yet not call Vertex the new SOC is obscure.

      • The other issue is how one defines interferon intolerence.

        It seems to me the the FDA will define it as those who have already taken it for a minimum number of weeks and decided to discontinue treatment because they showed intolerable side effects as verified by the doctor who treated them. If that is the FDA criteria, only a small percentage of patients fall into that category, e.g. those who dropped out before they completed their previous regimen. I say a small % because if you peruse through most of these HCV trials you will find out the drop out rates are not really that large--mostly into the teen percents.

118.41+3.26(+2.83%)Dec 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Fluor Corporation
NYSEFri, Dec 26, 2014 4:03 PM EST
Macy's, Inc.
NYSEFri, Dec 26, 2014 4:00 PM EST